Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
ApexOnco Front Page
Recent articles
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
The private ADC company is being wound down.
Two new PD-(L)1 x VEGF projects have entered the clinic.
Ideate-Lung02 goes on global clinical hold.
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
